Legend Biotech (LEGN) investor relations material

Strategic priorities and market expansion

• Maximizing CARVYKTI's market potential, with a focus on operational breakeven by year-end and profitability by 2026.

• Recent data show up to a third of heavily pretreated myeloma patients achieve five-year remission, considered a functional cure.

• Achieved label addition in Europe for survival data; awaiting similar FDA label update in the U.S.

• Two global phase 3 trials are underway to expand into frontline myeloma treatment, with readouts expected in the next few years.

• Deepening penetration into early-line and community settings is a key growth strategy.

Financial performance and market opportunity

• CARVYKTI posted $439 million in global net trade sales in Q2, becoming the top-selling CAR-T product worldwide.

• U.S. multiple myeloma market has a prevalence of 190,000, with 35,000–40,000 patients fitting the second-line label annually.

• Ex-U.S. revenue reached $81 million last quarter, with launches in Germany and Spain and presence in 11 ex-U.S. markets.

• Expansion in Europe is expected with the upcoming commercial license for the Techland facility, one of the largest cell therapy production sites.

Community and outpatient strategy

• CARVYKTI's delayed CRS onset allows for outpatient administration, with over half of commercial use now outpatient.

• Direct-to-patient campaigns and physician education are increasing awareness and referrals from community settings.

• Collaboration with Virginia Oncology Associates marks the first community-based CARVYKTI site, with plans to expand to more clinics and GPOs.

• Outpatient administration reduces costs, making it financially viable for community centers.